Premium
A randomised trial of two regimens of vaginal misoprostol to manage termination of pregnancy of up to 16 weeks
Author(s) -
KHAZARDOOST Soghra,
HANTOUSHZADEH Sedigheh,
MADANI Marjan Moezi
Publication year - 2007
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/j.1479-828x.2007.00721.x
Subject(s) - misoprostol , medicine , pregnancy , obstetrics , abortion , medical abortion , regimen , gestational age , gynecology , incomplete abortion , gestation , randomized controlled trial , surgery , genetics , biology
Objective: The purpose of this study was to compare the efficacy and side‐effects of two regimens of vaginal misoprostol for pregnancy termination of up to 16 weeks. Methods: A randomised clinical trial of medical pregnancy termination of up to 16 weeks was conducted. A hundred pregnant women requesting legal termination of pregnancy were randomised into two groups to receive either 200 µg (50 women) or 400 µg (50 women) – vaginal misoprostol every six hours up to four doses. Outcome of abortion and side‐effects were assessed. Results: The groups were similar in maternal age, gestational age, parity and indication for pregnancy termination. There were no statistically significant differences between the two groups in abortion ( P = 0.084) and mean induction to abortion time ( P = 0.35). However, the side‐effects in the 400 µg group were significantly higher than in the 200 µg group ( P = 0.000). Conclusion: In pregnancy termination of up to 16 weeks, 200 µg vaginal misoprostol every six hours up to four doses was as effective as 400 µg, but side‐effects were more common in 400 µg regimen.